ANAB - Anaptys to Present Phase 1 Data on ANB032 its BTLA Agonist Antibody at the 32nd EADV Congress | Benzinga
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032's previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032's Phase 2b study in moderate to severe atopic dermatitis.
The company's planned activities are listed below and the full preliminary program is available online on the EADV website.
Oral Presentation
ANB032, a novel BTLA agonist monoclonal antibody, inhibits T cell proliferation, reduces inflammatory cytokines, and down modulates BTLA expression on circulating T and B cells: Results from a first-in-human Phase 1 study (abstract #5603)
- Session Title – FC05: Free communications in biologics, immunotherapy and targeted therapy
- Session Date and Time – Friday, Oct. 13, 2023 from 8:30am – 10:40am CEST
- Presentation Time – 8:30am to 8:40am CEST
E-Poster Presentation
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects ...